MLTX · MoonLake Immunotherapeutics
United States · RS rating 32 · As of 2026-11-03
| Price | 11.70 USD |
|---|---|
| 1-day change | +2.0% |
| RS rating (overall / 1M / 3M / 12M) | 32 / 66 / 18 / 65 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 6 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +47.2% |
| Market cap (USD) | $1.2B |